Download PDF
Semin Liver Dis 2014; 34(03): 329-333
DOI: 10.1055/s-0034-1383731
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Natural History of Primary Biliary Cirrhosis

Mohamad H. Imam
1   Department of Internal Medicine, University of North Dakota, Fargo, North Dakota
,
Keith D. Lindor
2   College of Health Solutions, Arizona State University, Phoenix, Arizona
› Author Affiliations
Further Information

Publication History

Publication Date:
24 July 2014 (online)

    Permissions and Reprints

Abstract

Our understanding of the natural history of primary biliary cirrhosis (PBC) has been evolving especially following the introduction of ursodeoxycholic acid (UDCA). A clearer understanding of disease pathophysiology and earlier diagnosis with increased prevalence of the disease worldwide has led to increased interest and improved outcomes in patients with PBC. In this article, the authors touch briefly on features of the disease and describe the natural history of PBC prior to and after the introduction of UDCA.

Keywords

primary biliary cirrhosis - ursodeoxycholic acid - liver transplantation
 

  • References

  • 1 Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5 (11) 1313-1315
    CrossrefPubMedGoogle Scholar
  • 2 Mendes FD, Kim WR, Pedersen R, Therneau T, Lindor KD. Mortality attributable to cholestatic liver disease in the United States. Hepatology 2008; 47 (4) 1241-1247
    PubMedGoogle Scholar
  • 3 Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet 1987; 1 (8537) 834-836
    PubMedGoogle Scholar
  • 4 Prince MI, James OF. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003; 7 (4) 795-819
    CrossrefPubMedGoogle Scholar
  • 5 Matsumoto H. Mechanism of the pivot shift. J Bone Joint Surg Br 1990; 72 (5) 816-821
    PubMedGoogle Scholar
  • 6 Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353 (12) 1261-1273
    CrossrefPubMedGoogle Scholar
  • 7 Kitic I, Boskovic A, Stankovic I, Prokic D. Twelve-year-old girl with primary biliary cirrhosis. Case Rep Pediatr 2012; 2012: 937150
    PubMedGoogle Scholar
  • 8 Kim WR, Lindor KD, Locke III GR , et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119 (6) 1631-1636
    CrossrefPubMedGoogle Scholar
  • 9 James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV. Primary biliary cirrhosis once rare, now common in the United Kingdom?. Hepatology 1999; 30 (2) 390-394
    CrossrefPubMedGoogle Scholar
  • 10 Baldursdottir TR, Bergmann OM, Jonasson JG, Ludviksson BR, Axelsson TA, Björnsson ES. The epidemiology and natural history of primary biliary cirrhosis: a nationwide population-based study. Eur J Gastroenterol Hepatol 2012; 24 (7) 824-830
    CrossrefPubMedGoogle Scholar
  • 11 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 2009; 50 (1) 291-308
    CrossrefPubMedGoogle Scholar
  • 12 Solis Herruzo JA, Solis Munoz P, Munoz Yague T. The pathogenesis of primary biliary cirrhosis. Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva; 2009. 101. 413-423
    Google Scholar
  • 13 McNally RJ, James PW, Ducker S, James OF. Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology. Hepatology 2011; 54 (6) 2099-2103
    CrossrefPubMedGoogle Scholar
  • 14 Varyani FK, West J, Card TR. An increased risk of urinary tract infection precedes development of primary biliary cirrhosis. BMC Gastroenterol 2011; 11: 95
    CrossrefPubMedGoogle Scholar
  • 15 Chen RC, Naiyanetr P, Shu SA , et al. Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology 2013; 57 (4) 1498-1508
    CrossrefPubMedGoogle Scholar
  • 16 Sasaki M, Kakuda Y, Miyakoshi M, Sato Y, Nakanuma Y. Infiltration of inflammatory cells expressing mitochondrial proteins around bile ducts and in biliary epithelial layer may be involved in the pathogenesis in primary biliary cirrhosis. J Clin Pathol 2014; 67 (6) 470-476
    CrossrefPubMedGoogle Scholar
  • 17 Corpechot C, Gaouar F, Chrétien Y, Johanet C, Chazouillères O, Poupon R. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol 2012; 56 (1) 218-224
    CrossrefPubMedGoogle Scholar
  • 18 Hirschfield GM, Liu X, Xu C , et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009; 360 (24) 2544-2555
    CrossrefPubMedGoogle Scholar
  • 19 Jin Q, Moritoki Y, Lleo A , et al. Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology 2012; 55 (5) 1495-1506
    CrossrefPubMedGoogle Scholar
  • 20 Dinani AM, Fischer SE, Mosko J, Guindi M, Hirschfield GM. Patients with autoimmune hepatitis who have antimitochondrial antibodies need long-term follow-up to detect late development of primary biliary cirrhosis. Clin Gastroenterol Hepatol 2012; 10 (6) 682-684
    CrossrefPubMedGoogle Scholar
  • 21 Mattalia A, Quaranta S, Leung PS , et al. Characterization of antimitochondrial antibodies in health adults. Hepatology 1998; 27 (3) 656-661
    CrossrefPubMedGoogle Scholar
  • 22 Gatselis NK, Zachou K, Norman GL , et al. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity 2013; 46 (7) 471-479
    CrossrefPubMedGoogle Scholar
  • 23 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012; 12: CD000551
    PubMedGoogle Scholar
  • 24 Zhang Y, Lu J, Dai W , et al. Combination therapy of ursodeoxycholic acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis. Gastroenterol Res Pract 2013; 2013: 490731
    PubMedGoogle Scholar
  • 25 Ozaslan E, Efe C, Heurgue-Berlot A , et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol 2014; 12 (5) 863-869
    CrossrefPubMedGoogle Scholar
  • 26 Levy C, Naik J, Giordano C , et al. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics. Clin Gastroenterol Hepatol 2013;
    PubMedGoogle Scholar
  • 27 Boberg KM, Wisløff T, Kjøllesdal KS, Støvring H, Kristiansen IS. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment Pharmacol Ther 2013; 38 (7) 794-803
    CrossrefPubMedGoogle Scholar
  • 28 Papastergiou V, Tsochatzis EA, Rodriquez-Peralvarez M , et al. Biochemical criteria at 1.  year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. Aliment Pharmacol Ther 2013; 38 (11-12) 1354-1364
    CrossrefPubMedGoogle Scholar
  • 29 Carbone M, Mells GF, Pells G , et al UK PBC Consortium. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013; 144 (3) 560-569 , e7, quiz e13–e14
    CrossrefPubMedGoogle Scholar
  • 30 Kuiper EM, Hansen BE, Adang RP , et al; Dutch PBC Study Group. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2010; 22 (12) 1495-1502
    PubMedGoogle Scholar
  • 31 Myers RP, Swain MG, Lee SS, Shaheen AA, Burak KW. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol 2013; 108 (6) 933-941
    CrossrefPubMedGoogle Scholar
  • 32 Lens S, Leoz M, Nazal L , et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 2014; 34 (2) 197-203
    CrossrefPubMedGoogle Scholar
  • 33 Trivedi PJ, Kumagi T, Al-Harthy N , et al. Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2013;
    PubMedGoogle Scholar
  • 34 Neuberger J. Liver transplantation for primary biliary cirrhosis. Autoimmun Rev 2003; 2 (1) 1-7
    CrossrefPubMedGoogle Scholar
  • 35 Carbone M, Bufton S, Monaco A, Griffiths L, Jones DE, Neuberger JM. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol 2013; 59 (3) 490-494
    CrossrefPubMedGoogle Scholar
  • 36 Neuberger J, Portmann B, Macdougall BR, Calne RY, Williams R. Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med 1982; 306 (1) 1-4
    CrossrefPubMedGoogle Scholar
  • 37 Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33 (1) 22-27
    CrossrefPubMedGoogle Scholar
  • 38 Charatcharoenwitthaya P, Pimentel S, Talwalkar JA , et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007; 13 (9) 1236-1245
    CrossrefPubMedGoogle Scholar
  • 39 Sanchez EQ, Levy MF, Goldstein RM , et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 2003; 76 (11) 1583-1588
    CrossrefPubMedGoogle Scholar
  • 40 Levitsky J, Hart J, Cohen SM, Te HS. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl 2003; 9 (7) 733-736
    CrossrefPubMedGoogle Scholar
  • 41 Khettry U, Anand N, Faul PN , et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl 2003; 9 (1) 87-96
    CrossrefPubMedGoogle Scholar
  • 42 Sebagh M, Farges O, Dubel L, Samuel D, Bismuth H, Reynes M. Histological features predictive of recurrence of primary biliary cirrhosis after liver transplantation. Transplantation 1998; 65 (10) 1328-1333
    CrossrefPubMedGoogle Scholar
  • 43 Manousou P, Arvaniti V, Tsochatzis E , et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl 2010; 16 (1) 64-73
    CrossrefPubMedGoogle Scholar
  • 44 Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant 2010; 10 (4) 720-726
    CrossrefPubMedGoogle Scholar